FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031687309> ?p ?o ?g. }

• W2031687309 endingPage "357" @default.
• W2031687309 startingPage "351" @default.
• W2031687309 abstract "Antisense and Nucleic Acid Drug DevelopmentVol. 9, No. 4 An Antisense Oligonucleotide PrimerRICHARD I. HOGREFERICHARD I. HOGREFESearch for more papers by this authorPublished Online:30 Jan 2009https://doi.org/10.1089/oli.1.1999.9.351AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byGuidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs Keith T. Gagnon and David R. Corey30 May 2019 | Nucleic Acid Therapeutics, Vol. 29, No. 3Nanoparticles as nucleic acid delivery vectorsGene delivery for periodontal regenerationPersonalized Cancer Approach: Using RNA Interference Technology10 May 2011 | World Journal of Surgery, Vol. 35, No. 8Dosage Formulation15 March 2010Gene-Based Therapies for Lung Cancer8 January 2010Recent progress in oligonucleotide therapeutics: antisense to aptamers21 August 2008 | Expert Opinion on Drug Discovery, Vol. 3, No. 9Arginine-rich cell penetrating peptides: Design, structure–activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides1 January 2008 | Journal of Peptide Science, Vol. 14, No. 4Protection of oligodeoxynucleotides against nuclease degradation through association with self-assembling peptidesBiomaterials, Vol. 29, No. 8Synthesis and enzymatic stability of PEGylated oligonucleotide duplexes and their self-assemblies with polyamidoamine dendrimers1 January 2008 | Soft Matter, Vol. 4, No. 2Gene therapy applications for the treatment of neuropathic pain9 January 2014 | Expert Review of Neurotherapeutics, Vol. 7, No. 5Application of 2-Amino-6-Vinylpurine As an Efficient Agent for Conjugation of OligonucleotidesNucleosides, Nucleotides and Nucleic Acids, Vol. 25, No. 2Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopyJournal of Controlled Release, Vol. 110, No. 1Individualised cancer therapeutics: dream or reality?21 November 2005 | Expert Opinion on Therapeutic Targets, Vol. 9, No. 6Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer18 November 2005 | Clinical Cancer Research, Vol. 11, No. 22Chemical modification of gene silencing oligonucleotides for drug discovery and developmentDrug Discovery Today, Vol. 10, No. 8Gene Therapy for the Extension of Vein Graft Patency: A Review4 August 2016 | Vascular and Endovascular Surgery, Vol. 39, No. 1Challenges for RNAi in vivoTrends in Biotechnology, Vol. 22, No. 8What constitutes target validation?TARGETS, Vol. 2, No. 4Antisense therapeutics: from theory to clinical practicePharmacology & Therapeutics, Vol. 99, No. 1Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo Laixin Wang, Ramesh K. Prakash, C.A. Stein, Richard K. Koehn, and Duane E. Ruffner8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 13, No. 3Gene and Antisense Therapy of Bladder CancerCreation of Functional Recognition Molecules for Chemical Modification of Gene ExpressionYAKUGAKU ZASSHI, Vol. 122, No. 12Solid phase synthesis of oligonucleotides tethered to oligo-glucose phosphate tailsTetrahedron, Vol. 58, No. 33Discovery and Development of Respirable Antisense Therapeutics for Asthma Anthony Sandrasagra, Sherry A. Leonard, Lei Tang, Kelly Teng, Yukui Li, Howard A. Ball, James C. Mannion, and Jonathan W. Nyce8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 12, No. 3Polynucleotides15 March 2002BlasenkarzinomCoronary in-stent restenosis: Current status and future strategiesJournal of the American College of Cardiology, Vol. 39, No. 2Inhibition of GM-CSF/IL-3/IL-5 Signaling by Antisense Oligodeoxynucleotides Targeting the Common Beta Chain of Their Receptors Mustapha Allam and Paolo M. Renzi8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 11, No. 5Competitive Binding of Triplex-Forming Oligonucleotides in the Two Alternate Promoters of the PMP22 Gene Mehreen Hai, Sanjay I. Bidichandani, Michael E. Hogan, and Pragna I. Patel8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 11, No. 4Antisense Nucleic Acids in Biotechnology19 April 2001Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNAChemistry & Biology, Vol. 8, No. 1Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death7 December 1999 | Proceedings of the National Academy of Sciences, Vol. 96, No. 25Oligonucleotides as Radiopharmaceuticals Volume 9Issue 4Aug 1999 To cite this article:RICHARD I. HOGREFE.An Antisense Oligonucleotide Primer.Antisense and Nucleic Acid Drug Development.Aug 1999.351-357.http://doi.org/10.1089/oli.1.1999.9.351Published in Volume: 9 Issue 4: January 30, 2009PDF download" @default.
• W2031687309 created "2016-06-24" @default.
• W2031687309 creator A5015999420 @default.
• W2031687309 date "1999-08-01" @default.
• W2031687309 modified "2023-10-14" @default.
• W2031687309 title "An Antisense Oligonucleotide Primer" @default.
• W2031687309 cites W1496645167 @default.
• W2031687309 cites W1538612543 @default.
• W2031687309 cites W1564730852 @default.
• W2031687309 cites W1623759422 @default.
• W2031687309 cites W1921440765 @default.
• W2031687309 cites W1964414035 @default.
• W2031687309 cites W1969818257 @default.
• W2031687309 cites W1970206786 @default.
• W2031687309 cites W1971159711 @default.
• W2031687309 cites W1973223999 @default.
• W2031687309 cites W1982792956 @default.
• W2031687309 cites W1988711597 @default.
• W2031687309 cites W1989895357 @default.
• W2031687309 cites W1992368170 @default.
• W2031687309 cites W1994489381 @default.
• W2031687309 cites W1995599027 @default.
• W2031687309 cites W2004580736 @default.
• W2031687309 cites W2007404424 @default.
• W2031687309 cites W2008132588 @default.
• W2031687309 cites W2015290966 @default.
• W2031687309 cites W2021977857 @default.
• W2031687309 cites W2030799825 @default.
• W2031687309 cites W2038260132 @default.
• W2031687309 cites W2050230983 @default.
• W2031687309 cites W2052143871 @default.
• W2031687309 cites W2053138556 @default.
• W2031687309 cites W2063915751 @default.
• W2031687309 cites W2067401769 @default.
• W2031687309 cites W2070272639 @default.
• W2031687309 cites W2070799892 @default.
• W2031687309 cites W2073115409 @default.
• W2031687309 cites W2079271212 @default.
• W2031687309 cites W2081884104 @default.
• W2031687309 cites W2085069351 @default.
• W2031687309 cites W2089828669 @default.
• W2031687309 cites W2092119023 @default.
• W2031687309 cites W2092942407 @default.
• W2031687309 cites W2096739990 @default.
• W2031687309 cites W2101785219 @default.
• W2031687309 cites W2102877678 @default.
• W2031687309 cites W2107628126 @default.
• W2031687309 cites W2128456041 @default.
• W2031687309 cites W2136828884 @default.
• W2031687309 cites W2148320915 @default.
• W2031687309 cites W2155089348 @default.
• W2031687309 cites W2273900373 @default.
• W2031687309 doi "https://doi.org/10.1089/oli.1.1999.9.351" @default.
• W2031687309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10463079" @default.
• W2031687309 hasPublicationYear "1999" @default.
• W2031687309 type Work @default.
• W2031687309 sameAs 2031687309 @default.
• W2031687309 citedByCount "44" @default.
• W2031687309 countsByYear W20316873092017 @default.
• W2031687309 countsByYear W20316873092019 @default.
• W2031687309 crossrefType "journal-article" @default.
• W2031687309 hasAuthorship W2031687309A5015999420 @default.
• W2031687309 hasConcept C104317684 @default.
• W2031687309 hasConcept C129312508 @default.
• W2031687309 hasConcept C143141573 @default.
• W2031687309 hasConcept C14363569 @default.
• W2031687309 hasConcept C147789679 @default.
• W2031687309 hasConcept C153911025 @default.
• W2031687309 hasConcept C185592680 @default.
• W2031687309 hasConcept C24107716 @default.
• W2031687309 hasConcept C2777271071 @default.
• W2031687309 hasConcept C2908938912 @default.
• W2031687309 hasConcept C552990157 @default.
• W2031687309 hasConcept C55493867 @default.
• W2031687309 hasConcept C67705224 @default.
• W2031687309 hasConcept C86803240 @default.
• W2031687309 hasConceptScore W2031687309C104317684 @default.
• W2031687309 hasConceptScore W2031687309C129312508 @default.
• W2031687309 hasConceptScore W2031687309C143141573 @default.
• W2031687309 hasConceptScore W2031687309C14363569 @default.
• W2031687309 hasConceptScore W2031687309C147789679 @default.
• W2031687309 hasConceptScore W2031687309C153911025 @default.
• W2031687309 hasConceptScore W2031687309C185592680 @default.
• W2031687309 hasConceptScore W2031687309C24107716 @default.
• W2031687309 hasConceptScore W2031687309C2777271071 @default.
• W2031687309 hasConceptScore W2031687309C2908938912 @default.
• W2031687309 hasConceptScore W2031687309C552990157 @default.
• W2031687309 hasConceptScore W2031687309C55493867 @default.
• W2031687309 hasConceptScore W2031687309C67705224 @default.
• W2031687309 hasConceptScore W2031687309C86803240 @default.
• W2031687309 hasIssue "4" @default.
• W2031687309 hasLocation W20316873091 @default.
• W2031687309 hasLocation W20316873092 @default.
• W2031687309 hasOpenAccess W2031687309 @default.
• W2031687309 hasPrimaryLocation W20316873091 @default.
• W2031687309 hasRelatedWork W1998651635 @default.
• W2031687309 hasRelatedWork W2015649105 @default.
• W2031687309 hasRelatedWork W2036650790 @default.

• next